-+ 0.00%
-+ 0.00%
-+ 0.00%

Lytix Biopharma Cash and Short-Term Investments Fall to NOK 67.3 Million From NOK 91.4 Million

PUBT·11/13/2026 06:08:30
Lytix Biopharma Cash and Short-Term Investments Fall to NOK 67.3 Million From NOK 91.4 Million
  • Lytix Biopharma's cash and short-term financial investments fell to NOK 67.3 million as of September 30, 2026.
  • That compares with NOK 91.4 million as of June 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202611130100OSLOBORSNEWS__EN_D79161F09179AA5703DE24EFA1F53BC), on November 13, 2026, and is solely responsible for the information contained therein.